A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older with Moderate to Severe Atopic Dermatitis

The study will assess the safety, tolerability, and efficacy of IM Alefacept (Amevive) in patients with atopic dermatitis.

You may be eligible to participate in this study if you:

• Are 18 years of age or older
• Have been diagnosed with moderate to severe atopic dermatitis
• Are willing to withhold other atopic dermatitis medications during the course of the study

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.